ArticleCureus2025
Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Dobutamine, a β1-adrenergic agonist, is frequently used to enhance myocardial contractility in patients with critical illness. However, it also increases tachyarrhythmia and myocardial oxygen consumption. Landiolol, an ultra-short-acting and highly β1-selective β-blocker, is used to manage tachycardia in patients with critical illness; however, the combination of a β-agonist and β-blocker seems contradictory at first glance. Previous studies have examined this combination in healthy subjects; however, its effects on patients with critical illness have not been fully elucidated. Hence, this study aimed to address that gap in the literature. Methods This single-center, retrospective, observational study included adult ICU patients who received combination therapy with dobutamine and landiolol between January 1, 2014, and December 31, 2023. Patients who received combination therapy for less than 24 hours or who required extracorporeal circulatory support were excluded. Continuous hemodynamic data were extracted from electronic medical records. Primary outcomes were changes in heart rate (HR) and mean arterial pressure (MAP) after initiation of landiolol administration. Secondary outcomes were achievement of HR <110 bpm, incidence of hypotension (MAP <65 mmHg), change in lactate levels, and rhythm conversion in patients with atrial fibrillation (AF). Linear mixed-effects models were used to evaluate changes in HR and MAP after the initiation of landiolol treatment. Results A total of 72 patients were included in the final analysis. Landiolol treatment was significantly associated with a significant decrease in HR (β = -2.61, p < 0.001) without a significant decrease in MAP. Landiolol treatment also significantly decreased lactate levels (p = 0.029). In patients with atrial fibrillation (n = 53), 79.2 % converted to sinus rhythm or paced rhythm after the initiation of landiolol treatment. Conclusions Landiolol effectively reduced HR without reducing MAP in critically ill patients with dobutamine-induced tachycardia. Furthermore, landiolol may promote rhythm control and improve metabolic parameters such as lactate levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.